June 21, 2022

How A&M Helps Asset-light Pharma Companies Optimise the CMO Network for Growth

A well-performing CMO network is critical for asset-light pharma companies as the ability to supply is often the main hindrance to growth. Root causes of issues include becoming locked in with underperforming CMOs, not finding and building up alternatives, or failing to run transfers efficiently. In this article, we present the A&M Sourcing Decision Framework and show how we have practically used it to help our clients become more agile and structured to reshape their CMO network and support future growth.
 

Download 

 

Related Insights
As global challenges continue, asset-light pharmaceutical companies will remain under increased pressure for the rest of 2022 and beyond. How can asset-light companies create value in a disrupted market? A&M shares 5-value levers for asset-light pharmaceutical businesses.
Authors

Stefan Sanz-Velasco

Director

Torsten Schuth

Director
FOLLOW & CONNECT WITH A&M